

CV Date	24/02/2022
---------	------------

Part A. PERSONAL INFORMATION

First Name	Luzalba del Carmen		
Family Name	Sanoja Flores		
Open Researcher and Contributor ID (ORCID)	0000-0002-9275-7793		

A.1. Current position

Job Title	PhD researcher beneficiary of Post-doctoral Sara Borrell Spanish Grant		
Starting date	2022		
Institution	FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA		
Department / Centre	Group of cell therapy and new therapeutic targets in oncohematology / Institute of Biomedicine of Seville		
Country		Phone Number	
Keywords	Biological sciences		

A.2. Previous positions (Research Career breaks included)

Period	Job Title / Name of Employer / Country
2020 - 2021	PhD researcher / FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA
2014 - 2020	PhD student / Cancer Research Center of University of Salamanca
2008 - 2011	Biochemical analyst / Banco Municipal de Sangre. Caracas, Venezuela

A.3. Education

Degree/Master/PhD	University / Country	Year
Doctor in Bioscience: Biology and Clinical of Cancer, and Traslational Medicine	University of Salamanca	2020
Master: Biology and Clinical of Cancer	University of Salamanca	2014
Master: Specialist in Haematology Laboratory and Blood Bank managed	Pontificia University Javeriana. Bogotá, Colombia	2012
Bachelor degree: Bioanalysis	Central University of Venezuela. Caracas, Venezuela	2008

Part B. CV SUMMARY

Doctor of Bioscience at the University of Salamanca, Spain, with Cumlaude mention and Outstanding Prize of the PhD thesis. Currently, Post-doctoral Sara Borrell Grant beneficiary from Spanish "Instituto de Salud Carlos III" for 3 years (January 2022- December 2024) at the Institute of Biomedicine of Seville, Spain.

Her main knowledge area is based on hemopathies focusing in monitoring of multiple myeloma patients using novel and highly-sensitive next generation flow cytometry approaches to analyse minimal residual disease after treatment and circulating tumour plasma cells among plasma cells neoplasms patients.

H index of 10 with a total of 14 peer reviewed publications (4 of them as first author in Q1 scientific journals), which overall have >900 full citations.

Member of the CIBER-ONC consortium since 2017.

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Most important publications in national or international peer-reviewed journals, books and conferences

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 Scientific paper.** Noemi Puig; Juan Flores-Montero; Leire Burgos; et al; ;. (7/17). 2021. Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma *Cancers*. 13-4924, pp.1-12. <https://doi.org/doi.org/10.3390/cancers13194924>
- 2 Scientific paper.** Roberia Mendonça de Pontes; Juan Flores-Montero; Luzalba Sanoja-Flores; et al;. (3/25). 2021. B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients *Cancers*. 13-7, pp.1-8. <https://doi.org/10.3390/cancers13071704>
- 3 Scientific paper.** Daniela Damasceno; Julia Almeida; Cristina Teodosio; et al; ;. (4/17). 2021. Monocyte subsets and serum inflammatory and bone-associated markers in monoclonal gammopathy of undetermined significance and multiple myeloma *Cancers*. 13-6, pp.1-17. <https://doi.org/10.3390/cancers13061454>
- 4 Scientific paper.** Juan-José Garcés; Gabriel Bretones; Leire Burgos; et al; ;. (16/33). 2020. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma *Leukemia*. 34-11, pp.3007-3018. <https://doi.org/10.1038/s41375-020-0883-0>
- 5 Scientific paper.** Bruno Paiva; Noemi Puig; Maria-Teresa Cedená; et al; ;. (9/35). 2020. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma *Journal of Clinical Oncology*. 38-8, pp.784-792. <https://doi.org/10.1200/JCO.19.01231>
- 6 Scientific paper.** Juan José Garcés; Michal Simicek; Marco Vicari; et al; ;. (25/36). 2020. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination *Leukemia*. 34-2, pp.589-603. <https://doi.org/10.1038/s41375-019-0588-4>
- 7 Scientific paper.** Luzalba Sanoja Flores; Juan Flores Montero; Noemi Puig; et al;. (1/24). 2019. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy *Blood*. 134-24, pp.2218-2222. <https://doi.org/10.1182/blood.2019002610>
- 8 Scientific paper.** Juan Flores-Montero; Tomas Kalina; Alba Corral-Mateos; et al; ;. (4/14). 2019. Fluorochrome choices for multi-color flow cytometry *Journal of Immunological Methods*. 475, pp.1-9. <https://doi.org/10.1016/j.jim.2019.06.009>
- 9 Scientific paper.** Sanoja-Flores L; Flores-Montero J; Garcés JJ; et al; Orfao A. (1/30). 2018. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). *Blood cancer journal*. 8-12, pp.117. <https://doi.org/10.1038/s41408-018-0153-9>
- 10 Scientific paper.** Elena Blanco; Martín Pérez Andrés; Luzalba Sanoja Flores; et al; Orfao A. (3/16). 2017. Selection and validation of antibody clones against IgG and IgA subclasses in switched memory B-cells and plasma cells *Journal of Immunological Methods*. pp.1-12. <https://doi.org/10.1016/j.jim.2017.09.008>
- 11 Scientific paper.** Juan Flores Montero; Luzalba Sanoja Flores; Bruno Paiva; et al; Orfao A. (1/33). 2017. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma *Leukemia*. 31-10, pp.2094-2103. <https://doi.org/10.1038/leu.2017.29>

- 12 Scientific paper.** Juan Flores Montero; Ruth de Tute; Bruno Paiva; et al; ; Orfao A. (7/12). 2015. Immunophenotype of Normal vs. Myeloma Plasma Cells: Toward Antibody Panel Specifications for MRD Detection in Multiple Myeloma Cytometry Part B. 90-B, pp.61-72. <https://doi.org/10.1002/cyto.b.21265>
- 13 Scientific paper.** Fanny Pojero; Juan Flores Montero; Luzalba Sanoja Flores; et al; Orfao A. (3/9). 2015. Utility of CD54, CD229, and CD319 for the Identification of Plasma Cells in Patients with Clonal Plasma Cell Diseases.Cytometry Part B. 90-B, pp.91-100. <https://doi.org/10.1002/cyto.b.21269>
- 14 Review.** Luzalba Sanoja Flores; Juan Flores Montero; Martín Pérez Andrés; Noemí Puig; Alberto Orfao. (1/5). 2020. Detection of circulating tumor plasma cells in monoclonal gammopathies: Methods, pathogenic role, and clinical implications Cancers. 12-6, pp.1-26. <https://doi.org/10.3390/cancers12061499>

C.3. Research projects and contracts

- 1 Project.** Predicción de la respuesta del tratamiento con células CAR-T: búsqueda de biomarcadores y medición de la actividad metabólica mediante monitorización inmune. Teresa Caballero. (Complejo Hospitalario Virgen del Rocío). 03/01/2022-31/12/2024.
- 2 Project.** Immune monitoring/profiling project proposal. Alberto Orfao. (Cancer Research Center). 01/01/2020-31/12/2020. 207.817,05 €.
- 3 Project.** Identification of circulating tumor plasma cells in peripheral blood of multiple myeloma vs MGUS: clinical impact and implications in disease behavior. International Myeloma Foundation. (Cancer Research Center). 01/04/2016-30/03/2019. 105.600 €.